Phaseline

Targets › EDNRB

EDNRB (Endothelin receptor type B): drug programs, companies and trials

7 programs from 6 companies in 14 trials: 6 Phase 3, 5 Phase 2, 3 Phase 4; Neurology, Cardiovascular, Other; next expected readout Nov 2026.

Non-specific receptor for endothelin 1, 2, and 3. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. (UniProt, P24530)

Open in Phaseline: the race on EDNRB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PharmazzSovateltide
ETB receptor agonist
EDNRBPhase 4Acute Cerebral Ischemia; Acute Ischemic Stroke; Hypoxic-Ischemic EncephalopathyNov 2026
Johnson & Johnson (Janssen)Macitentan
Endothelin receptor, ET-A/ET-B antagonist
EDNRB, EDNRAPhase 3Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Combined Pre- and Post-capillary Pulmonary HypertensionJan 2027
University Hospital, Grenoblebosentan
Endothelin receptor, ET-A/ET-B antagonist
EDNRB, EDNRAPhase 3Ischemic Optic NeuropathyFeb 2027
University of EdinburghBosentan
Endothelin receptor, ET-A/ET-B antagonist
EDNRB, EDNRAPhase 2Large Vessel VasculitisJul 2027
Noorik BiopharmaceuticalsAmbrisentan
Endothelin receptor, ET-A/ET-B antagonist
EDNRB, EDNRAPhase 2Hepatorenal Syndrome; IgA Nephropathy; Pulmonary Arterial Hypertension (PAH)–
University Hospital, RouenBosentan
Endothelin receptor, ET-A/ET-B antagonist
EDNRB, EDNRAPhase 2Resistant Hypertension–
PharmazzPMZ-1620
Endothelin-B receptor agonist
EDNRBPhase 2Acute Spinal Cord Injury–

Conditions

Hypertension, Pulmonary (2) Ischemic Optic Neuropathy (1) Acute Spinal Cord Injury (1) Acute Cerebral Ischemia (1) Acute Ischemic Stroke (1) Hypoxic-Ischemic Encephalopathy (1) Hepatorenal Syndrome (1) IgA Nephropathy (1) Pulmonary Arterial Hypertension (PAH) (1) Resistant Hypertension (1) Large Vessel Vasculitis (1) Pulmonary Arterial Hypertension (1)

Modalities

small molecule (5), protein or peptide (2)

Companies

Pharmazz (2) University Hospital, Grenoble (1) Noorik Biopharmaceuticals (1) University Hospital, Rouen (1) University of Edinburgh (1) Johnson & Johnson (Janssen) (1)

Related targets

EDNRA (5)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.